GlassScriptPhysician profile
Megan Hottel
NPI 1730602426
$7,976.73
in general payments reported to CMS, 2019-2025
35 companies · $1,637 in 2025
The $1,637 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $384 · 2022: $2,047 · 2023: $2,034 · 2024: $1,875 · 2025: $1,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,064 · Education: $482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,063.89 |
| Education | $482.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,778.24 | 2021-2025 | |
| Janssen Biotech, INC. | $964.74 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $639.15 | 2022-2025 | |
| Lilly USA, LLC | $624.04 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $571.71 | 2022-2025 | Blu-U, Winlevi, Absorica Ld |
| Incyte Corporation | $429.70 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $360.97 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $330.41 | 2022-2025 | Dupixent, Libtayo |
| Pfizer INC. | $288.72 | 2021-2025 | |
| Amgen INC. | $253.45 | 2022-2025 | Otezla, Otezla |
| Ucb, INC. | $221.98 | 2022-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $176.37 | 2022-2025 | Arazlo, Cabtreo |
| Leo Pharma INC. | $163.83 | 2023-2025 | Adbry, Anzupgo |
| Mayne Pharma Commercial LLC | $144.65 | 2022-2025 | |
| Genzyme Corporation | $105.05 | 2022-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $99.63 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Journey Medical Corporation | $93.11 | 2022 | |
| Galderma Laboratories, L.P. | $89.52 | 2022-2025 | Nemluvio, Aklief |
| Sanofi-Aventis U.S. LLC | $79.99 | 2023 | |
| Dermavant Sciences, INC. | $63.20 | 2022-2024 | Vtama |
| Janssen Pharmaceuticals, INC | $58.47 | 2024-2025 | Tremfya |
| Convatec INC. | $55.47 | 2024 | |
| Arcutis Biotherapeutics, INC. | $48.82 | 2023 | |
| Genentech USA, INC. | $44.45 | 2021-2023 | Erivedge |
| Verrica Pharmaceuticals INC. | $39.52 | 2024 | Ycanth |
| Botanix Sb INC | $39.37 | 2025 | Sofdra |
| Biofrontera INC. | $36.03 | 2022-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Dexcom, INC. | $34.04 | 2024 | Dexcom G6 Transmitter |
| Organon LLC | $30.26 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.35 | 2024 | Spevigo |
| Organogenesis INC. | $21.25 | 2024 | Puraply Am |
| Fresenius Kabi USA, LLC | $19.44 | 2023 | |
| Kyowa Kirin, INC. | $17.36 | 2022 | |
| Almirall LLC | $16.87 | 2024 | Seysara |
| Boston Scientific Corporation | $12.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Hottel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.